Breakthrough! Or maybe not ...

This week's success in Aids drug trials is good news. But scientists have reason to be cautious, says Steve Connor

The venue was a room in the Sheraton Hotel at Heathrow Airport. About 20 of the world's leading Aids researchers had gathered to listen to the latest results of a large clinical trial of anti-HIV drugs. As medical protocol demanded, they had until now all been deliberately kept in the dark about data from the ''double blind'' trial, when neither doctor nor patient knows exactly who is taking which drug. It is standard procedure to prevent experimental bias.

When the International Co-ordinating Committee of the Delta trial heard the results of the two-year follow-up of 3,000 patients from eight countries, an unusual silence descended around the table. They needed time to absorb the magnitude of what they were being told, and perhaps check themselves from thinking they had heard it all before. They could even be forgiven for experiencing a feeling of deja vu. It was not the first time that they were being told to stop an Aids drug trial because the results were so good - to continue would be unethical, given that some patients were deliberately being deprived of what had now become the best treatment.

Yet the results were plain to see. The Delta trial showed that two drugs were better than one at preventing death from Aids over two to three years. In fact, death rates had been reduced by almost 40 per cent in the group taking two drugs compared with the group taking one.

The Heathrow meeting happened two weeks ago yesterday. It took the committee several days to agree on a public statement, which they wanted to make as soon as possible to tell patients and doctors of the results. The news emerged earlier this week and made headlines throughout the world. Many newspapers, included this one, heralded it as a breakthrough.

This was indeed the first real hope since 1986, when a previous clinical trial appeared to show that one drug, AZT, was better than none at all. That trial, too, had been stopped for ethical reasons, albeit after only six months.

Yet it must have played on the minds of many of the scientists at the Delta results meeting that, by stopping short this latest trial, they might end up repeating a mistake made with the earlier 1986 "breakthrough''.

That trial, it turned out, was ended prematurely. Six months into the experiment, it was clear that patients using AZT were benefiting. Out of 145 people taking the drug, only one had died, compared with 19 deaths in the placebo group of 137 who took nothing but a sugar pill. About twice as many in the placebo group had also developed Aids. However, after the trial had been stopped, as time went on, the advantages of taking AZT began to become less apparent. It subsequently emerged that AZT at best can only buy a little extra time, perhaps a year, and even then at the risk of some pretty dreadful side-effects.

Most Aids researchers today feel it was a mistake to stop this 1986 trial before the true limitations of AZT could be seen. But 1986 was a time of unprecedented pressure on the medical community to come up with any Aids treatment that worked. ''The simple message then was to get drugs into bodies now,'' says Nick Partridge, chief executive of the Terrence Higgins Trust, an Aids charity. ''There was a very strong demand from the patients themselves for AZT to be made available as soon as possible.''

Gay pressure groups in Britain and the US lobbied hard for AZT, which was the only drug to show any signs of being able to limit the replication of HIV in an infected person. For a short period at the end of the Eighties, it was the only ''lifeline of hope'' offered to people with HIV and Aids, Mr Partridge says.

That was a difficult time for medical scientists who wanted to establish proper clinical trials - when a randomly chosen group of patients taking a new drug are compared against those given placebo. Scientists are particularly interested in ''clinical end points'', which in the case of Aids often means waiting until someone dies. It may seem a brutal form of experimentation, but such double-blind, placebo-controlled trials are the most powerful method of determining whether a drug works in prolonging life.

The problems of testing AZT in clinical trials have been made worse by suggestions that some patients taking part have deliberately tried to circumvent scientific protocols. Some patients involved in earlier trials have deliberately mixed their medication with that of friends to limit the risk of being given a useless placebo.

Despite such difficulties, British and French scientists planned in 1988 what was then the largest clinical trial of AZT in both Aids patients and HIV-infected people without symptoms. The trial, called Concorde, involved 1,749 patients being followed over a three-year period. Preliminary results of the trial, released in a letter to the Lancet in April 1993, showed that AZT was no better than a placebo at preventing death or the onset of Aids in healthy, HIV-positive people.

After three years, 92 per cent of the AZT group were still alive, compared with 93 per cent survival in the placebo group. In both groups, 18 per cent had gone on to develop Aids and side-effects were significantly more common in the AZT group.

Concorde helped to fuel a growing backlash against AZT on both sides of the Atlantic. The Terrence Higgins Trust was picketed by Aids patients for being too closely linked with Wellcome and its AZT, and a vociferous minority of Aids activists began a campaign, alleging it was the drug, rather than HIV, that was the cause of the disease. The disappointment in AZT helped to foster a climate of new age anti-science within sections of the Aids community who felt the answer to the disease rested with alternative therapies rather than synthetic drugs.

Part of the reason why the Concorde trial was a crushing disappointment for the Aids community was to do with how the caveats and uncertainties of scientific research are translated for a wider public. Undoubtedly, the 1986 clinical trial was interpreted as a ''breakthrough'' (which was subsequently shattered) but this is not a term most scientists ever use. Their preferred phrases, such as ''significant step forward'', do not have quite the same impact with a headline-hunting media.

It was unusual, therefore, for journalists to be told not to play down the significance of the Delta trial results earlier this week. Patients taking both AZT in combination with one of two other anti-viral drugs, called ddI (didanosine) and ddC (zalcitabine), were significantly less likely to die during the period of the trial. Reduction in death rates over the course of the trial was 38 per cent for patients who took two drugs compared with those taking AZT alone. The data showed that 17 per cent of participants who took AZT alone died during the trial, compared with 10 per cent of those who took AZT with ddi and 12 per cent of those who took AZT with ddC.

''We were very surprised at the extent of the effect,'' says Brian Gazzard, UK trial co-ordinator and director of the Aids unit at London's Chelsea and Westminster Hospital. ''This is the first study with long-term follow- up in which survival has been changed dramatically. It establishes once and for all that anti-viral drugs can prolong life.''

Tim Peto, consultant in infectious diseases at the John Radcliffe Hospital in Oxford, who was at the hotel room meeting at Heathrow two weeks ago, was equally adamant that the Delta trial represented the most significant research into Aids treatment for nearly 10 years. His optimism is shared by Professor Alasdair Breckendridge of Liverpool University who chairs the UK Co-ordinating Committee for Delta. ''It is important not to underestimate what has been shown,'' he says.

It seems such optimism is unlikely to be displaced. At an international Aids meeting in Copenhagen yesterday, it became clear that an American drugs trial similar to Delta supports the two-drug approach of combination therapy. Professor Tony Pinching of St Bartholomew's Hospital in London, said: "Clinicians are now seriously persuaded by this data, which they weren't earlier in the week. It is good to see doctors on both sides of the Atlantic coming together. The feelings in the corridor are that we now have enough firm data to act on."

The next stage is to see whether three or more drugs are better than two. The Medical Research Council has already set up a trial of four drugs taken in combination to test the idea in yet another clinical trial.

Unfortunately, unanswered questions remain about combination therapy. The Delta trial does not tell scientists when is the best time to start using the drugs and for how long to continue. It also does not make clear whether people already being treated with AZT get any long-term benefit from switching to the two-drug approach. ''While these drug combinations can slow progression to Aids, they do not prevent it, and the increase in life expectancy is probably still quite small,'' Nick Partridge says.

So can the Delta trial, after all, warrant the label of a genuine breakthrough? Yes and no, says Tim Peto. ''It's a breakthrough in the sense that future research will proceed in a logical and sensible way, and so if the finding influences future research, then it's a breakthrough.''

And how many breakthroughs make a cure? ''Well you need a least another three, four or five to get that.''

News
The surrealist comedian at the Q Awards in 2010
people
News
Russell Brand arriving for the book launch in East London
peopleRussell Brand cancels his book launch debate due to concerns about the make-up of the panel
Sport
Christiano Ronaldo enjoys his opening goal
champions leagueLiverpool 0 Real Madrid 3: Ronaldo and Benzema run Reds ragged to avenge thrashing from their last visit to Anfield
Arts and Entertainment
Awesome foursome: Sam Smith shows off his awards
music22-year-old confirms he is 2014’s breakout British music success
PROMOTED VIDEO
Have you tried new the Independent Digital Edition apps?
News
ebooksAn unforgettable anthology of contemporary reportage
Life and Style
Six of the 76 Goats' cheese samples contained a significant amount of sheep's cheese
food + drink
Arts and Entertainment
Contestants during this summer's Celebrity Big Brother grand finale
tvBroadcaster attempts to change its image following sale to American media group
Extras
indybest
Arts and Entertainment
Sir Nicholas Serota has been a feature in the Power 100 top ten since its 2002 launch
art
Arts and Entertainment
Sarah Dales attempts to sell British Breeze in the luxury scent task
tvReview: 'Apprentice' candidate on the verge of tears as they were ejected from the boardroom
News
Call me Superman: one of many unusual names chosen by Chinese students
newsChinese state TV offers advice for citizens picking a Western moniker
News
Wilko Johnson is currently on his farewell tour
people
Voices
New look: Zellweger at Elle's Women in Hollywood awards on Monday
voicesRenée Zellweger's real crime has been to age in an industry that prizes women's youth over humanity, says Amanda Hess
News
Let’s pretend: KidZania in Tokyo
educationKidZania lets children try their hands at being a firefighter, doctor or factory worker for the day
Life and Style
CHARGE BOOSTER: Aeroplane mode doesn't sound very exciting, but it can be a (phone) hacker's friend. Turning on the option while charging your mobile will increase the speed at which your phone battery charges
techNew book reveals how to rid your inbox of spam, protect your passwords and amplify your iPhone
Arts and Entertainment
Julianne Moore and Ellen Page are starring together in civil rights drama Freeheld
film
Latest stories from i100
Have you tried new the Independent Digital Edition apps?
Independent Dating
and  

By clicking 'Search' you
are agreeing to our
Terms of Use.

iJobs Job Widget
iJobs General

Solutions Architect - Permanent - London - £70k DOE

£60000 - £70000 Per Annum Excellent benefits: Clearwater People Solutions Ltd:...

General Cover Teacher

£110 - £130 per day: Randstad Education Reading: Great opportunities for Cover...

Maths Teacher

£110 - £130 per day: Randstad Education Reading: QTS Maths Teachers needed for...

Maths Teacher

£110 - £130 per day: Randstad Education Reading: QTS Maths Teachers needed for...

Day In a Page

How could three tourists have been battered within an inch of their lives by a burglar in a plush London hotel?

A crime that reveals London's dark heart

How could three tourists have been battered within an inch of their lives by a burglar in a plush London hotel?
Meet 'Porridge' and 'Vampire': Chinese state TV is offering advice for citizens picking a Western moniker

Lost in translation: Western monikers

Chinese state TV is offering advice for citizens picking a Western moniker. Simon Usborne, who met a 'Porridge' and a 'Vampire' while in China, can see the problem
Handy hacks that make life easier: New book reveals how to rid your inbox of spam, protect your passwords and amplify your iPhone

Handy hacks that make life easier

New book reveals how to rid your email inbox of spam, protect your passwords and amplify your iPhone with a loo-roll
KidZania lets children try their hands at being a firefighter, doctor or factory worker for the day

KidZania: It's a small world

The new 'educational entertainment experience' in London's Shepherd's Bush will allow children to try out the jobs that are usually undertaken by adults, including firefighter, doctor or factory worker
Renée Zellweger's real crime has been to age in an industry that prizes women's youth over humanity

'Renée Zellweger's real crime was to age'

The actress's altered appearance raised eyebrows at Elle's Women in Hollywood awards on Monday
From Cinderella to The Jungle Book, Disney plans live-action remakes of animated classics

Disney plans live-action remakes of animated classics

From Cinderella to The Jungle Book, Patrick Grafton-Green wonders if they can ever recapture the old magic
Thousands of teenagers to visit battlefields of the First World War in new Government scheme

Pupils to visit First World War battlefields

A new Government scheme aims to bring the the horrors of the conflict to life over the next five years
The 10 best smartphone accessories

Make the most of your mobile: 10 best smartphone accessories

Try these add-ons for everything from secret charging to making sure you never lose your keys again
Mario Balotelli substituted at half-time against Real Madrid: Was this shirt swapping the real reason?

Liverpool v Real Madrid

Mario Balotelli substituted at half-time. Was shirt swapping the real reason?
West Indies tour of India: Hurricane set to sweep Windies into the shadows

Hurricane set to sweep Windies into the shadows

Decision to pull out of India tour leaves the WICB fighting for its existence with an off-field storm building
Indiana serial killer? Man arrested for murdering teenage prostitute confesses to six other murders - and police fear there could be many more

A new American serial killer?

Police fear man arrested for murder of teen prostitute could be responsible for killing spree dating back 20 years
Sweetie, the fake 10-year-old girl designed to catch online predators, claims her first scalp

Sting to trap paedophiles may not carry weight in UK courts

Computer image of ‘Sweetie’ represented entrapment, experts say
Fukushima nuclear crisis: Evacuees still stuck in cramped emergency housing three years on - and may never return home

Return to Fukushima – a land they will never call home again

Evacuees still stuck in cramped emergency housing three years on from nuclear disaster
Wildlife Photographer of the Year: Intimate image of resting lions claims top prize

Wildlife Photographer of the Year

Intimate image of resting lions claims top prize
Online petitions: Sign here to change the world

Want to change the world? Just sign here

The proliferation of online petitions allows us to register our protests at the touch of a button. But do they change anything?